Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP‐5862, in patients with B‐cell malignancies and in healthy subjects using a population pharmacokinetic approach

This analysis aimed to describe the pharmacokinetics (PK) of acalabrutinib and its active metabolite, ACP‐5862. A total of 8935 acalabrutinib samples from 712 subjects and 2394 ACP‐5862 samples from 304 subjects from 12 clinical studies in patients with B‐cell malignancies and healthy subjects were...

Descripción completa

Detalles Bibliográficos
Autores principales: Edlund, Helena, Bellanti, Francesco, Liu, Huan, Vishwanathan, Karthick, Tomkinson, Helen, Ware, Joseph, Sharma, Shringi, Buil‐Bruna, Núria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290582/
https://www.ncbi.nlm.nih.gov/pubmed/34265100
http://dx.doi.org/10.1111/bcp.14988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290582/
https://www.ncbi.nlm.nih.gov/pubmed/34265100
http://dx.doi.org/10.1111/bcp.14988

Ejemplares similares